UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of incor ...

财务数据和关键指标变化 - 2021年全年赠款收入为310万美元，2020财年为70万美元，增长约343% [21] - 2021年全年研发费用为1140万美元，2020年为90万美元，增长约1167% [23] - 2021年全年销售、一般及行政费用为650万美元，2020年同期为260万美元，增长约150% [24] - 2021年全年净亏损约1480万美元，即每股0.81美元，2020年全年净亏损约280万美元，即每股0.35美元 [25] - 截至2021年12月31日，公司现金约4080万美元，预计现金可支持运营至2023年第三季度 [25] 各条业务线数据和关键指标变化 IKT - 148009帕金森病项目 - 随机1期剂量递增研究在老年健康志愿者中评估安全性、耐受性和药代动力学，2021年2月启动，320毫克剂量下曲线下面积大于200,000纳克·小时/毫升，单次或7天给药实验中88名受试者至325毫克剂量无临床显著不良事件，脑脊液检测证实可穿透中枢神经系统 [11] - 1B期扩展研究是3:1随机安慰剂对照剂量递增试验，在轻度至中度晚期帕金森病患者中评估7天给药的安全性、耐受性和药代动力学，首批入组分析的8名患者中无临床显著不良事件，仅观察到1例肺炎、1例腰椎穿刺后头痛和1例皮炎 [13] IKT - 148009多系统萎缩项目 - 正在动物模型中评估IKT - 148009，若在至少一种动物模型中看到积极治疗效果，且与FDA和欧盟等效监管机构达成协议，可能在2022年第三季度推进至2a期临床研究 [17][19] IKT - 001Pro项目 - 正在收集产品稳定性数据，预计2022年第二季度提交新药研究申请，收到研究结果并与FDA达成其他协议后，将按照505(b)(2)监管途径开展最终关键研究 [20] 公司战略和发展方向和行业竞争 - 公司转型为临床阶段公司，推进主要项目IKT - 148009用于帕金森病治疗进入临床，在早期管线中推进IKT - 148009在多系统萎缩动物模型研究及IKT - 001Pro的新药研究申请提交 [7][8] - 计划在2022年第二季度启动IKT - 148009的2a期临床研究，评估其在多达120名未进展到需要症状治疗的帕金森病患者中的安全性和耐受性 [16] 管理层对经营环境和未来前景的评论 - 2021年是重要一年，公司在短时间内取得显著进展，认为这些努力为管线执行奠定基础，有望改善患者生活并为股东创造价值 [7] - 对公司工作感到兴奋，认为有机会显著改善帕金森病等神经退行性疾病患者的生活，将2022年视为所有临床和临床前管线项目的执行年 [27] 其他重要信息 - 公司将在4月20日的虚拟关键意见领袖投资者活动中分享更多关于IKT - 148009的发展战略和近期公布的数据，包括即将开展的2a期研究 [27] 总结问答环节所有的提问和回答 文档中未提及问答环节的提问和回答内容。

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 26-3407249 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-3407249 ( State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-3407249 ( State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorpora ...